Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
Aktis Oncology reported a cash position of $517.3 million as of June 30, 2026, bolstered by net proceeds from its January IPO, which extends the company's runway into 2029. The company disclosed positive first-in-human clinical imaging and dosimetry data for AKY-2519 at ASCO, demonstrating robust tumor uptake and limited normal tissue exposure, while initiating Phase 1b trials for both AKY-2519 and AKY-1189.
Key figures
- Revenue
- 3400000
- Guidance
- GMP facility expected operational H2 2026; preliminary data from AKY-1189 trial expected Q1 2027; preliminary data from AKY-2519 mCRPC trial expected 2027
- Runway
- into 2029
- Net loss
- 24100000
- Ga expenses
- 7000000
- Rd expenses
- 25300000
- Cash position
- 517300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.